Regulation of cell adhesion by PAI-1

APMIS. 1999 Jan;107(1):54-61. doi: 10.1111/j.1699-0463.1999.tb01526.x.


Type I plasminogen activator inhibitor (PAI-1) is the primary inhibitor of tissue- and urokinase-type plasminogen activators. It circulates in plasma complexed with vitronectin (VN), the primary PAI-1 binding protein. The somatomedin B (SMB) domain of VN contains both the high affinity PAI-1 binding site and the specific site for urokinase plasminogen activator receptor (uPAR). PAI-1 is able to regulate uPAR-mediated cell adhesion by competing with uPAR for VN binding. Binding of PAI-1 to SMD may also affect integrin-mediated cell adhesion to VN by hindering integrin binding to the RGD sequence adjacent to the uPAR binding site.

Publication types

  • Review

MeSH terms

  • Animals
  • Binding Sites
  • Cell Adhesion*
  • Humans
  • Plasminogen Activator Inhibitor 1 / physiology*
  • Receptors, Cell Surface / physiology
  • Receptors, Urokinase Plasminogen Activator
  • Vitronectin / physiology


  • PLAUR protein, human
  • Plasminogen Activator Inhibitor 1
  • Receptors, Cell Surface
  • Receptors, Urokinase Plasminogen Activator
  • Vitronectin